Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ph 1 Study of Escalating Single & Multiple Doses of Mana 312 (Multi Tumor-Associated Antigen T Cells) Administered to Adult Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplant

NCT04679194 is registered in ClinicalTrials.gov with Mana Therapeutics as lead sponsor.

NCT NCT04679194
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04679194 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ph 1 Study of Escalating Single & Multiple Doses of Mana 312 (Multi Tumor-Associated Antigen T Cells) Administered to Adult Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplant
Lead sponsor
Mana Therapeutics
Phase
Phase 1
Overall status
Terminated
Start date
December 8, 2020
Completion date
March 28, 2023
Enrollment
11 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

aml/mds